Jardiance Joy Boosts Boehringer Ingelheim

Leading the pack with partner Lilly in the expansion of diabetes medication into cardiovascular protection, Boehringer Ingelheim looks set to build this year on its healthy 2016 growth. The completion of its acquisition of Sanofi's Mérial animal health business in January will also boost future sales.

Hitting bigger business target
Boehringer Ingelheim is aiming bigger in diabetes • Source: Shutterstock

Boehringer Ingelheim GMBH reported 56.1% currency-adjusted growth in its diabetes business in 2016, and from 2017 the early lead in the use of diabetes medication for cardiovascular indications that it and partner Eli Lilly & Co. have established looks likely to help drive continued expansion.

The family-owned German company revealed that total global sales of the SGLT-2 inhibitor Jardiance (empagliflozin) were €433m in 2016, with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.